化疗联合应用帕米膦酸钠治疗肿瘤骨转移的疗效  

Efficacy of chemotherapy combined with pamidronate disodium in treatment of cancer bone metastasis

作　　者：李丽[1] 钱晓萍[1] 刘宝瑞[1] 

机构地区：[1]南京大学医学院附属鼓楼医院肿瘤中心,江苏省210008

出　　处：《江苏医药》2013年第1期33-35,共3页Jiangsu Medical Journal

基　　金：南京市医学科技发展项目(QYK09164)

摘　　要：目的观察化疗联合应用帕米膦酸钠治疗肿瘤骨转移的疗效。方法 60例肿瘤骨转移患者均分为两组,A组为化疗联合应用帕米膦酸钠,B组仅单纯化疗。记录治疗前、后体力状况评分(KPS)、疼痛评分(NRS)和血清碱性磷酸酶(AKP)浓度变化。结果治疗2个周期后,两组血清AKP水平明显低于治疗前,且A组AKP下降程度大于B组(P<0.05)。治疗后,两组NRS评分有明显降低,而KPS评分有明显升高(P<0.05),且A组改善效果较B组更好。A组疼痛缓解率为66.67%,明显高于B组的46.67%(P<0.05)。治疗期间无骨相关事件发生。结论化疗联合应用帕米膦酸钠治疗肿瘤骨转移性疼痛疗效优于单纯化疗;血清AKP可作为疗效评估指标。Objective To evaluate the clinical efficacy of chemotherapy combined with pamidronate disodium in treatment of cancer bone metastasis. Methods Sixty patients with bone metastasis cancer were equally divided into two groups of A（treated with chemotherapy combined with pamidronate disodium） and B（treated with chemotherapy alone）. Serum alkaline phosphatase（AKP） was measured and the pain scores（NRS）, skeletal-related events （SREs） and Karnofsky performance status（KPS） were evaluated before and after two cycles treatments. Results After treament for two cycles, serum AKP of two groups was significantly decreased, which was more in group A than that in group B（P〈0. 05）. NRS score was decreased, KPS score was increased in two groups after treament, which were more in group A than those in group B（P〈0. 05）. The pain relief rate was more in group A than that in group B（66. 67% vs. 46.67%） （P〈0.05）. SREs were not observed during the treatment. Conclusion The clinical efficacy of chemotherapy combined with pamidronate disodium is more than that of chemotherapy alone in the treatment of cancer with bone metastases. Serum AKP may be taken as an indicator for evaluating the therapeutic effect.

关 键 词：帕米膦酸钠 肿瘤骨转移 碱性磷酸酶 

分 类 号：R730[医药卫生—肿瘤]